EN — 简 — FR
Diversified Pipeline
Discovered Using Pharma.AI
INNOVATIVE AND ACCELERATED INTERNAL DRUG CANDIDATES
  • 31
    Total Number of Programs
  • 29
    Total Number of Targets
  • 2
    Preclinical Candidates Nominated in 2021
  • 9
    Preclinical Candidates Nominated in 2022
Programs below progressed beyond early pre-clinical. Many programs are available under CDA.
Contact bd@insilicomedicine.com for partnering opportunities
Target
Phase 2
Phase 1
IND-enabling
Discovery
Stage of development
Other
Oncology
Immunology
Fibrosis
TARGET X* — Undisclosed target.
Co-development with Fosun
Mechanism
EPO induction and iron utilization, epithelial integrity
Tumor cell proliferation
Virus replication
Immune modulation
Synthetic lethality
Tumor cell proliferation
Synthetic lethality
Epigenetics
Immune modulation
EMT, FMT,
fibroblast proliferation,
macrophage activation
indication
Inflammatory Bowel Disease
Anemia of Chronic Kidney Disease
Skin Fibrosis
Hepatocellular carcinoma (HCC)
COVID-19
Solid tumors
BRCA-mutant cancer
Solid tumors
MTAP-/- cancer
ER+/HER2- breast cancer
Immuno-Oncology
Kidney Fibrosis
Idiopathic Pulmonary Fibrosis
PHD
3CLPro
USP1
MAT2A
KAT6A
QPCTL
cMYC
CDK12
DGKA
Target X*
Immune modulation
Solid tumors
ENPP1
COLLABORATIONS
AND PARTNERSHIPS
The rapid progress of internal pipeline demonstrates the generative-AI driven drug discovery capabilities of our Pharma.AI platform consisting of PandaOmics, Chemistry42, and inClinico.

Our collaboration partners can leverage our technology and development capabilities to augment and accelerate their discovery and development initiatives.
TARGET X
Target X Inhibitor: Treating Fibrotic diseases of the Lung, Kidney and Skin
PHD
Proline Hydroxylase (PHD) Inhibitors: Treatment of Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD)
QPCTL
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Inhibitor: Novel cancer immunotherapy for COLD tumors
USP1
Ubiquitin Specific Protease 1 (USP1) Inhibitor for the treatment of BRCA-mutant cancer
MAT2A
Methionine adenosyltransferase 2α (MAT2A) Inhibitor: Treatment of MTAP Deficient Cancer
3CLPro
Orally Available covalent irreversible 3CLPro Inhibitor for the Treatment of COVID-19 and Coronavirus infection
KAT6A
KAT6A Inhibitor: Treatment of ER+/HER2- Breast Cancer
DGKA
Diacylglycerol kinase A (DGKA) Inhibitors: Treating solid tumors in combination with checkpoint inhibitors
CDK8/19
Cyclin Dependent Kinase 8/19 (CDK8/19) Inhibitors: Treating Tumors with Deregulated Transcription
CDK12
Cyclin-dependent kinase 12 (CDK12) Inhibitors: Treating Tumors byInduction of BRCAness
ENPP1
Ectonucleotide phosphodiesterase 1(ENPP1) Inhibitors: Treating anti-PD1 antibody resistance cancers
PARP7
213123